Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2/3, Randomized, Double-Blinded, Placebo-Controlled, Parallel-Group Study to Investigate the Efficacy and Safety of Efgartigimod PH20 SC in Adult Participants with Bullous Pemphigoid

Next Previous
Trial Profile

A Phase 2/3, Randomized, Double-Blinded, Placebo-Controlled, Parallel-Group Study to Investigate the Efficacy and Safety of Efgartigimod PH20 SC in Adult Participants with Bullous Pemphigoid

Status: Completed
Phase of Trial: Phase II/III

Latest Information Update: 07 Nov 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Efgartigimod alfa (Primary) ; Prednisone
  • Indications Bullous pemphigoid
  • Focus Registrational; Therapeutic Use
  • Acronyms ARGX113-2009; BALLAD
  • Sponsors argenx

Most Recent Events

  • 31 Oct 2024 According to an Argenx media release, update on BALLAD study development plan is expected by the end of 2024.
  • 11 Oct 2024 Status changed from active, no longer recruiting to completed.
  • 09 May 2024 According to an Argenx media release, Update on this study is expected by end of 2024

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top